612 completed, 181 terminated, 149 recruiting, 133 unknown. 1274 Phase 2, 245 Phase 1, 52 Phase 3.
Follow Rituximab: new trials by email Literature Review of Rituximab trials Research Report on Rituximab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 271 | 2027-07-27 | 2026-11-17 |
| Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies C9/CD5CAR/IL-15 NK cells, Rituximab, Fludarabine - Hematological Malignancies | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 70 | 2027-02-28 | 2026-08-20 |
| Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | City of Hope Medical Center | 58 | 2026-12-21 | 2026-10-22 |
| A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010) MK-1045, Zilovertamab vedotin, Rituximab - Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Merck Sharp & Dohme LLC | 470 | 2026-12-13 | 2026-11-05 |
| Pirtobrutinib With Sonrotoclax and Rituximab for High-Risk Relapsed/Refractory Mantle-Cell Lymphoma Following Covalent BTK-Inhibitor Failure Pirtobrutinib, Sonrotoclax, Rituximab injection - Mantle Cell Lymphoma (MCL), Relapsed/Refractory Mantle Cell Lymphoma (MCL) | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 35 | 2026-12-08 | 2026-11-18 |
| Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis Therapeutic Plasma Exchange, Rituximab, Intravenous immunoglobulin - Idiopathic Pulmonary Fibrosis | Phase 2 | Not yet recruiting | University of Alabama at Birmingham | 52 | 2026-12-01 | 2026-10-20 |
| The CARDIOPROTECT Trial Dexrazoxane, Dexrazoxane placebo, Doxorubicin - Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity | Phase 2 | Not yet recruiting | Beth Israel Deaconess Medical Center | 60 | 2026-12-01 | 2026-11-06 |
| Tafasitamab, Lenalidomide, Rituximab, and Orelabrutinib for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Tafasitamab, Lenalidomide, Rituximab - Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 29 | 2026-12-01 | 2026-11-16 |
| Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma Rituximab, Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisolone (R-CHOP), Epcoritamab, Dexamethasone - Non-Hodgkin's B-cell Lymphoma, Lymphoma Non-Hodgkin | Phase 2 | Not yet recruiting | Carrie Ho, MD | 20 | 2026-11-15 | 2026-10-01 |
| Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO) Loncastuximab tesirine, Rituximab or rituximab biosimilar - Post-transplant Lymphoproliferative Disorder | Phase 1 / Phase 2 | Recruiting | University of Utah | 23 | 2026-11-05 | 2026-11-09 |
| Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 35 | 2026-10-23 | 2026-10-29 |
| A Phase II Study of TT-01488 Tablets in Combination With Anti-CD20 Monoclonal Antibody Therapy in Patients With Mantle Cell Lymphoma TT-01488 Tablets, Rituximab, Immunomodulatory Agent - Mantle Cell Lymphoma (MCL) | Phase 2 | Not yet recruiting | TransThera Sciences (Nanjing), Inc. | 188 | 2026-10-10 | 2026-10-02 |
| Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma Rituximab, Tafasitamab, Biospecimen Collection - Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma | Phase 2 | Recruiting | University of Washington | 30 | 2026-10-09 | 2026-10-15 |
| Rituximab vs Placebo for Maintenance in Systemic Sclerosis - Interstitial Lung Disease Rituximab, Placebo - Systemic Sclerosis in Adults | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 120 | 2026-10-01 | 2026-09-18 |
| Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies NX-5948, venetoclax, rituximab - B-cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Nurix Therapeutics, Inc. | 150 | 2026-09-30 | 2026-11-16 |
| Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Adult Burkitt Lymphoma | Phase 2 | Recruiting | AIDS Malignancy Consortium | 43 | 2026-09-16 | 2026-11-17 |
| Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL Lisaftoclax (APG-2575), Rituximab, Pirtobrutinib - Richter Syndrome | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 23 | 2026-09-01 | 2026-09-21 |
| Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) Birelentinib, Rituximab, Cyclophosphamid - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 / Phase 3 | Not yet recruiting | Dizal Pharmaceuticals | 880 | 2026-09-01 | 2026-08-05 |
| A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma BL-M08D1, Rituximab, Gemcitabine Hydrochloride - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 204 | 2026-09-01 | 2026-09-14 |
| The HIt HArd and hiT Early in Multiple Sclerosis Trial Sequential treatment with rituximab and cladribine - Relapsing-remitting Multiple Sclerosis | Phase 2 | Recruiting | Uppsala University | 60 | 2026-09-01 | 2026-10-22 |
Showing 20 of 1274. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (277) · Lymphoma (274) · Lymphoma, Non-Hodgkin (208) · Leukemia, Lymphocytic, Chronic, B-Cell (183) · Lymphoma, Follicular (183) · Lymphoma, Mantle-Cell (161) · Lymphoma, B-Cell, Marginal Zone (104) · Leukemia (88) · Burkitt Lymphoma (80) · Waldenstrom Macroglobulinemia (75) · Lymphoma, B-Cell (69) · Recurrence (61) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (58) · Hodgkin Disease (42) · Lymphoma, Large-Cell, Immunoblastic (42)
M.D. Anderson Cancer Center (113) · National Cancer Institute (NCI) (57) · Hoffmann-La Roche (33) · Memorial Sloan Kettering Cancer Center (25) · Mayo Clinic (20) · Dana-Farber Cancer Institute (17) · Alliance for Clinical Trials in Oncology (16) · Ruijin Hospital (16) · University of Washington (16) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (15) · Weill Medical College of Cornell University (15) · City of Hope Medical Center (13) · Massachusetts General Hospital (13) · National Institute of Allergy and Infectious Diseases (NIAID) (13) · Northwestern University (13)
United States (743) · China (152) · France (102) · Italy (92) · United Kingdom (87) · Germany (85) · Spain (74) · Canada (59) · Australia (45) · South Korea (43) · Belgium (42) · Poland (36) · Netherlands (33) · Czechia (30) · Sweden (29)
Elias Jabbour (7) · Craig Moskowitz, MD (6) · Ajay Gopal (5) · Daniel O. Persky, MD (5) · Lode J. Swinnen, MD (5) · Richard Burt, MD (5) · Robert O. Dillman, MD, FACP (5) · Wyndham H Wilson, M.D. (5) · Anil Tulpule, MD (4) · Clive S. Zent, MD (4)
PMID 39319495, PMID 41671463, PMID 34515338, PMID 39513526, PMID 40550489, PMID 30125215, PMID 30575311, PMID 32770353, PMID 35622074, PMID 35787017, PMID 16551963, PMID 23470153, PMID 23753028, PMID 23834234, PMID 23861248, PMID 24224624, PMID 24802773, PMID 25568347, PMID 26083430, PMID 26132314, PMID 26373676, PMID 27022122, PMID 27282998, PMID 29054815, PMID 29358183, PMID 31208944, PMID 32705923, PMID 33735476, PMID 34797699, PMID 35882475, PMID 35952327, PMID 38271621, PMID 38551807, PMID 38941593, PMID 40802906, PMID 10387937, PMID 10552938, PMID 10845940, PMID 10997973, PMID 11222360, PMID 11509929, PMID 11981005, PMID 12011123, PMID 12070007, PMID 12353309, PMID 12384926, PMID 12393429, PMID 12488408, PMID 12620412, PMID 12637469
2015 (16), 2023 (13), P30CA015704 (13), U10CA031946 (13), U10CA032102 (13), P30CA015083 (11), 2009 (10), P30CA033572 (10), P30CA006973 (9), P30CA016672 (8), 2014 (7), 2005 (6), 2018 (6), U10CA021115 (6), U10CA180821 (6)